- Registered Clinical Trials
Hepatocellular Carcinoma / NSCLC
CAR-GPC3 T cell: the second generation of CAR-T with a humanized scFv targeting GPC3 for treatment of hepatocellular carcinoma and lung squamous carcinoma.
(B-Cell Maturation Antigen)
CAR-BCMA T cell: the second generation of CAR-T with a fully human scFv targeting BCMA for treatment of multiple myeloma.
B Cell Leukemia / Lymphoma
CAR-CD19 T cell : the second generation of CAR-T with a humanized scFv targeting CD19 for treatment of lymphoma.
IND In Preparation
Gastric / Pancreatic / Esophageal Cancer
CAR-CLDN18.2 T cell : the second generation of CAR-T with a humanized scFv targeting claudin18.2 for treatment of gastric and pancreatic cancer.
(Epidermal Growth Factor Receptor/variant3)
GBM / Other Solid Tumor
CAR-EGFR/EGFRvIII T cell :the second generation of CAR-T product with a humanized scFv targeting over-expressed EGFR as well as EGFRvIII for treatment of GBM (Glioblastoma Multiforme).
*: First-In-Human (means the first clinical trial for the CAR-T cells directed to the said target)